Home » Clinical Trials » Leukemia » NCT07244380
NCT07244380

A Phase II Clinical Trial of S101 Autologous CAR-T Cell Injection for the Treatment of CD7-Positive Relapsed or Refractory T-Lymphoblastic Lymphoma/Leukemia (T-LBL/ALL).

Study Summary

To Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.

Want to learn more about this trial?

Request More Info

Interventions

Autologous CD7-targeting CAR T cellsBIOLOGICAL
Autologous CD7-targeting CAR T cells, dosage 2\*10\^6/kg, intravenous injection once

Study Locations

No locations listed.

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026